Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $498000.0.

  • Protalix BioTherapeutics' Capital Expenditures rose 47241.38% to $498000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 4995.48%. This contributed to the annual value of $1.3 million for FY2024, which is 1157.53% up from last year.
  • Protalix BioTherapeutics' Capital Expenditures amounted to $498000.0 in Q3 2025, which was up 47241.38% from $310000.0 recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Capital Expenditures high stood at $598000.0 for Q1 2024, and its period low was $58000.0 during Q3 2022.
  • Its 5-year average for Capital Expenditures is $302789.5, with a median of $310000.0 in 2025.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Capital Expenditures tumbled by 8313.95% in 2022, and later surged by 67068.97% in 2023.
  • Protalix BioTherapeutics' Capital Expenditures (Quarter) stood at $448000.0 in 2021, then plummeted by 52.46% to $213000.0 in 2022, then increased by 17.37% to $250000.0 in 2023, then soared by 70.0% to $425000.0 in 2024, then rose by 17.18% to $498000.0 in 2025.
  • Its Capital Expenditures was $498000.0 in Q3 2025, compared to $310000.0 in Q2 2025 and $427000.0 in Q1 2025.